Status:
COMPLETED
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus
Lead Sponsor:
AstraZeneca
Conditions:
Diabetes Mellitus, Non-Insulin-Dependent
Eligibility:
All Genders
16-75 years
Phase:
PHASE3
Brief Summary
This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be random...
Eligibility Criteria
Inclusion
- Subjects with Type 2 diabetes mellitus
- Treated with both metformin and a sulfonylurea at defined doses for at least 3 months prior to screening
- BMI= 27-45 kg/m2
- HbA1c value between 7.5% and 11%
Exclusion
- Treated with oral anti-diabetic medications other than metformin and sulfonylurea within 3 months of screening
- Patients treated previously with AC2993
- Patients presently treated with insulin
Key Trial Info
Start Date :
May 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2003
Estimated Enrollment :
734 Patients enrolled
Trial Details
Trial ID
NCT00035984
Start Date
May 1 2002
End Date
August 1 2003
Last Update
February 24 2015
Active Locations (100)
Enter a location and click search to find clinical trials sorted by distance.
1
Pinnacle Research Group
Anniston, Alabama, United States, 36207
2
Parkway Medical Center
Birmingham, Alabama, United States, 35206
3
Extended Arm Physicians/ Southern Drug
Montgomery, Alabama, United States, 36106
4
Southern Drug Research Network
Tallassee, Alabama, United States, 36078